Navigation Links
Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
Date:3/13/2008

Pickering earned his B.S. degree in marketing from the Pennsylvania State University in University Park, PA and his MBA degree with honors from Georgetown University in Washington, DC.

In commenting on the appointment, Martin D. Cleary, Founder and Chairman of the Board of Directors said, "We are delighted that Grant has chosen to join our organization. Juvaris has proven to be an amazing company with tremendous potential that will truly impact the field of mono-immunotherapy and vaccines. Grant brings to Juvaris a skill set which is entirely relevant to the long-term needs of our company. We welcome him to Juvaris. When we started this company in February 2003, I had great expectations. Over the past five years, those expectations have only increased. It is now time to turn leadership over to Grant and enable him to successfully move Juvaris to the next level."

Thomas P. Monath, M.D. of Kleiner Perkins Caufield & Byers commented, "Grant's inspirational leadership skills, strategic vision, and experience in product development provide a recipe for success of Juvaris. The Company is expected to make huge strides this year that will demonstrate the utility of its technology in the clinic. We are extremely pleased that Grant will lead the Company through these milestones and on to commercial success."

"I am thrilled to join Juvaris at this critical time as the Company prepares to initiate clinical studies in multiple indications with its lead compound, JVRS-100," said Mr. Pickering. "I look forward to working with the talented group of employees, marquee investors, physicians and scientists that have contributed to Juvaris' progress to date."

About Juvaris

Juvaris BioTherapeutics is developing an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create JVRS-100, a lipid-DNA complex, which as a single produc
'/>"/>

SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
2. Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industrys Only Enterprise Quality Improvement System
3. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
4. Bionovo Announces 2007 Financial Results and Highlights
5. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
6. Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement
7. Providence Service Corporation Announces Fourth Quarter 2007 Revenue and Earnings Above Forecast; Issues First Quarter 2008 Guidance
8. Medifast Announces Year-end 2007 Financial Results
9. Immtech Announces Update on Business Operations
10. IOF announces Progress in Osteoporosis now available free online
11. Omnicell Announces Completion of Its Common Stock Repurchase Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... A new medical-testing device is being prepped to ... could improve diagnosis of certain diseases in remote ... a series of investigations aboard the International Space ... uses the space-tested concept of capillary flow to ... , David Kelso, Ph.D., a researcher at Northwestern ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , MONDAY, March 14 (HealthDay News) -- Women may ... a diet rich in two types of B vitamins, a ... and riboflavin (B2) in their food significantly reduced their risk ... fortified cereals, whole grains, beans and nuts, and researchers said ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, March ... that is, a pediatrician or nurse they see regularly who offers ... dental needs met, new research finds. Yet it,s the sickest ... and require the most care -- who are less likely to ...
... the globe are making headway in fighting communicable diseases ... research from the Frederick S. Pardee Center for International ... School of International Studies. The center ... volumes that focus on human progress in which researchers ...
... human studies of an oral drug regimen to prevent HIV ... in HIV incidence, but a number of issues require additional ... a large scale, according to an article in AIDS ... Mary Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... Research and Education recently received a five year, $3.7 ... and Agriculture to fund a project aimed at preventing ... to teach mothers simple yet authoritative strategies to promote ... The grant was awarded to Jenifer Orlet Fisher, associate ...
... ,Scientists at the National Institute of Allergy and Infectious ... have shown how the O157:H7 strain of Escherichia ... host immune response. The bacterium secretes a protein called ... alter specific immune responses. This process not only helps ...
Cached Medicine News:Health News:Diets Rich in Vitamin B May Help Prevent PMS, Study Finds 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:DU researchers find that headway being made fighting communicable diseases globally 2Health News:DU researchers find that headway being made fighting communicable diseases globally 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Temple receives $3.7 million to study parenting styles' effect on childhood obesity 2
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
(Date:1/14/2014)... FRANCISCO , Jan. 14, 2014 Spark Therapeutics , ... for its most advanced clinical program, a Phase 3 study for ... gene. Spark,s CEO, Jeffrey D. Marrazzo , is presenting this ... Healthcare Conference in San Francisco . Marrazzo said ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... officials in FDA,s Office of New Drugs (OND), the ... a cardiovascular outcomes trial (CVOT) for Contrave® that would ... 2011. Orexigen believes that these design requirements are reasonable ...
... CLEVELAND, Sept. 20, 2011 Dr. Melisa Estes, who is ... suffer from chronic knee pain. She recently began incorporating a ... nerve stimulation, also known as TENS, sends electrical stimulation to ... signals from reaching the brain, and that reduces pain. ...
Cached Medicine Technology:Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5Knee Pain Control - No Drugs - Doctor Used 2
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Developed in a Microsoft Windows environment, MedInformatix provides physician practices a Computerized Patient Record (CPR) with a Practice Management System (PMS) that is both integrated and design...
Medicine Products: